ABSTRACT

Cardiovascular disease [CVD] is the leading cause of death worldwide, and dyslipidemia is a key factor associated with an increased CVD risk. Although statin therapy is the first-line treatment for dyslipidemia, many sufferers do not attain their maximum capabilities low-density lipoprotein-cholesterol [LDL-C] levels even after taking moderate- or high-intensity statins; thus, non-statin therapy is frequently required. Bempedoic acid is a prodrug that, when activated, lowers LDL-C levels in the liver by inhibiting adenosine triphosphate citrate lyase. Bempedoic acid is approved by the FDA in 2020. On other hand Statins inhibitors of the hydroxymethyl glutaryl-CoA [HMG-CoA] reductase enzyme, are molecules of fungal origin. Statins are powerful cholesterol-lowering medications that operate by impeding a vital step in the sterol biosynthetic pathway. They have made contributions in prevention of CVD. Statins represent the cornerstone for the treatment of hypercholesterolemia, although muscle-related side effect are inevitable. This review is not a comparative but a descriptive analysis of Statins and Bempedoic acid. Keywords: Hyperlipidemia; LDL-C; ACL, Adenosine triphosphate-citrate lyase; Dyslipidemia
Publication date: 01/05/2023

https://ijbpas.com/pdf/2023/May/MS_IJBPAS_2023_7116.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.5.7116